The Single Injection

DFNB9 is genetic deafness caused by mutations in the OTOF gene, which encodes otoferlin — a protein required for synaptic transmission between cochlear hair cells and auditory nerve fibers. Without otoferlin, hair cells detect sound vibrations normally but cannot transmit the signal. The wiring is intact. The sensor works. The synapse is silent.

The condition was considered permanent. Inner ear hair cells in humans do not regenerate. Gene therapy for the inner ear faced a delivery problem: the cochlea is enclosed in bone, surrounded by fluid, and inaccessible to standard systemic delivery. Any intervention would need to reach the right cells in a sealed compartment.

Researchers delivered an AAV vector carrying a functional copy of OTOF through a single intracochlear injection. Ten patients — aged 1.5 to 24 years — with profound deafness (hearing thresholds around 106 decibels, meaning they could not hear a chainsaw) received one injection in one ear.

Within one month, hearing improved to moderate levels — thresholds dropped to 52 decibels. Patients aged five to eight responded best. One seven-year-old regained near-normal hearing within four months. The improvement was sustained for the duration of follow-up.

The mechanism is direct: the virus infects inner hair cells, they begin producing otoferlin, synaptic transmission resumes. No cell replacement, no regeneration, no rewiring. The existing hardware was functional — it lacked one protein. The injection supplied it.

The inversion is therapeutic: a condition classified as permanent, caused by a genetic defect in non-regenerating cells, corrected by a single delivery of the missing gene. The cells were waiting. They had been waiting since birth, structurally complete, capable of everything except the one function that mattered.